Anavex Life Sciences Corp. (AVXL)
NASDAQ: AVXL · Real-Time Price · USD
3.370
+0.080 (2.43%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Anavex Life Sciences Employees
Anavex Life Sciences had 34 employees as of September 30, 2025. The number of employees decreased by 8 or -19.05% compared to the previous year.
Employees
34
Change (1Y)
-8
Growth (1Y)
-19.05%
Revenue / Employee
n/a
Profits / Employee
-$1,174,912
Market Cap
312.30M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Abeona Therapeutics | 226 |
| Cabaletta Bio | 156 |
| LENZ Therapeutics | 152 |
| Coherus Oncology | 147 |
| Nautilus Biotechnology | 130 |
| Foghorn Therapeutics | 106 |
| Zentalis Pharmaceuticals | 106 |
AVXL News
- 14 days ago - Anavex Life Sciences Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts
- 14 days ago - Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer's Disease - GlobeNewsWire
- 21 days ago - Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Anavex Life Sciences Provides Comprehensive Regulatory Update - GlobeNewsWire
- 4 weeks ago - Anavex Life Sciences Stock Crushed As European Alzheimer's Drug Filing Pulled After EMA Pushback - Benzinga
- 4 weeks ago - Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease - GlobeNewsWire
- 5 weeks ago - Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer's Disease - GlobeNewsWire
- 5 weeks ago - New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer's Disease - GlobeNewsWire